



FACT SHEET As of 12/31/21

PROSHARES ULTRA NASDAQ BIOTECHNOLOGY

Fund objective

ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology® Index.

Fund details

Inception Date	4/7/10
Trading Symbol	BIB
Intraday Symbol	BIB.IV
Bloomberg Index Symbol	NBI
CUSIP	74347R214
Exchange	NASDAQ
Net Assets	\$194.72 million
Gross Expense Ratio	1.08%
Net Expense Ratio ¹	0.95%

Uses for magnified exposure

Common uses for magnified exposure include:

- Seeking magnified gains (will also magnify losses)
- Getting a target level of exposure for less cash
- Overweighting a market segment without additional cash


Fund performance and index history²

ProShares Ultra Nasdaq Biotechnology seeks a return that is 2x the return of its index (target) **for a single day**, as measured from one NAV calculation to the next. Due to the compounding of daily returns, holding periods of greater than one day can result in returns that are significantly different than the target return and ProShares' returns over periods other than one day will likely differ in amount and possibly direction from the target return for the same period. These effects may be more pronounced in funds with larger or inverse multiples and in funds with volatile benchmarks. Investors should monitor their holdings as frequently as daily. Investors should consult the prospectus for further details on the calculation of the returns and the risks associated with investing in this product.

	4Q 2021	Year to Date	1-Year	5-Year	10-Year	Fund Inception
ProShares Ultra Nasdaq Biotechnology NAV Total Return	-14.41%	-5.91%	-5.91%	15.29%	25.07%	22.52%
ProShares Ultra Nasdaq Biotechnology Market Price Total Return	-14.55%	-6.02%	-6.02%	15.24%	25.03%	22.51%
Nasdaq Biotechnology Index	-6.85%	0.02%	0.02%	11.88%	16.34%	15.10%

Periods greater than one year are annualized.


Daily performance of BIB vs. index during 4Q 2021



Correlation³= 0.99
Beta⁴= 2.00

The scatter graph charts the daily NAV-to-NAV results of the fund against its underlying index return on a daily basis.


Daily return during 4Q 2021



The performance quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance quoted. Performance data current to the most recent month-end may be obtained by calling 866.776.5125 or visiting ProShares.com. Index performance does not reflect any management fees, transaction costs or expenses. Indexes are unmanaged and one cannot invest directly in any index.

Carefully consider the investment objectives, risks, charges and expenses of ProShares before investing. This and other information can be found in their summary and full prospectuses. Read them carefully before investing. Obtain them from your financial professional or visit ProShares.com. ProShares are not suitable for all investors.

¹Expenses with Contractual Waiver through September 30, 2022. Without the fee waiver performance would likely be lower. ²Returns are based on the composite closing price and do not represent the returns you would receive if you traded shares at other times. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date. ³Correlation³ is a measure of the strength and direction of a linear relationship between two variables. ⁴Beta⁴ is a measure of the slope, which is the steepness of the line drawn through the fund return vs. the benchmark return on a daily basis. ©2021 PSA 2020-2440

<h2>Index description</h2> <p>The Nasdaq Biotechnology Index is a modified capitalization-weighted index that includes securities of The Nasdaq Stock Market listed companies that are classified as either biotechnology or pharmaceutical. The securities also meet other eligibility criteria determined by The Nasdaq Group Inc., including minimum market capitalization and liquidity requirements.</p>	<h3>Top 10 index companies</h3> <table border="1"> <thead> <tr> <th></th> <th>Weights</th> </tr> </thead> <tbody> <tr><td>Amgen Inc.</td><td>9.22%</td></tr> <tr><td>Gilead Sciences Inc.</td><td>7.36%</td></tr> <tr><td>Moderna Inc.</td><td>5.87%</td></tr> <tr><td>Illumina Inc.</td><td>5.39%</td></tr> <tr><td>AstraZeneca plc-Sponsored ADR</td><td>4.80%</td></tr> <tr><td>Biogen Inc.</td><td>4.51%</td></tr> <tr><td>Horizon Therapeutics plc</td><td>2.85%</td></tr> <tr><td>BioNTech SE-ADR</td><td>2.85%</td></tr> <tr><td>Alnylam Pharmaceuticals Inc.</td><td>2.28%</td></tr> <tr><td>Biomarin Pharmaceutical Inc.</td><td>1.97%</td></tr> </tbody> </table>		Weights	Amgen Inc.	9.22%	Gilead Sciences Inc.	7.36%	Moderna Inc.	5.87%	Illumina Inc.	5.39%	AstraZeneca plc-Sponsored ADR	4.80%	Biogen Inc.	4.51%	Horizon Therapeutics plc	2.85%	BioNTech SE-ADR	2.85%	Alnylam Pharmaceuticals Inc.	2.28%	Biomarin Pharmaceutical Inc.	1.97%
	Weights																						
Amgen Inc.	9.22%																						
Gilead Sciences Inc.	7.36%																						
Moderna Inc.	5.87%																						
Illumina Inc.	5.39%																						
AstraZeneca plc-Sponsored ADR	4.80%																						
Biogen Inc.	4.51%																						
Horizon Therapeutics plc	2.85%																						
BioNTech SE-ADR	2.85%																						
Alnylam Pharmaceuticals Inc.	2.28%																						
Biomarin Pharmaceutical Inc.	1.97%																						
<h2>Index characteristics</h2> <table border="1"> <tbody> <tr><td>Number of Companies</td><td>373</td></tr> <tr><td>Average Market Cap</td><td>\$4.51 billion</td></tr> <tr><td>Price/Book Ratio</td><td>4.67</td></tr> <tr><td>Dividend Yield</td><td>0.75%</td></tr> <tr><td>Volatility⁵</td><td>16.98%</td></tr> </tbody> </table>	Number of Companies	373	Average Market Cap	\$4.51 billion	Price/Book Ratio	4.67	Dividend Yield	0.75%	Volatility ⁵	16.98%	<h3>Index sectors</h3> <table border="1"> <thead> <tr> <th></th> <th>Weights⁶</th> </tr> </thead> <tbody> <tr><td>Biotechnology</td><td>78.52%</td></tr> <tr><td>Pharmaceuticals</td><td>11.04%</td></tr> <tr><td>Life Sciences Tools & Services</td><td>8.78%</td></tr> <tr><td>Health Care Providers & Services</td><td>0.96%</td></tr> <tr><td>Health Care Equipment & Supplies</td><td>0.70%</td></tr> </tbody> </table> 		Weights ⁶	Biotechnology	78.52%	Pharmaceuticals	11.04%	Life Sciences Tools & Services	8.78%	Health Care Providers & Services	0.96%	Health Care Equipment & Supplies	0.70%
Number of Companies	373																						
Average Market Cap	\$4.51 billion																						
Price/Book Ratio	4.67																						
Dividend Yield	0.75%																						
Volatility ⁵	16.98%																						
	Weights ⁶																						
Biotechnology	78.52%																						
Pharmaceuticals	11.04%																						
Life Sciences Tools & Services	8.78%																						
Health Care Providers & Services	0.96%																						
Health Care Equipment & Supplies	0.70%																						
<p>For more information, visit ProShares.com or ask your financial advisor or broker.</p>																							

⁵"Volatility" refers to annualized standard deviation, a statistical measure that captures the variations from the mean of an index's returns and that is often used to quantify the risk of the index over a specific time period. The higher the volatility, the more an index's returns fluctuate over time. ⁶Sum of weightings may not equal 100% due to rounding.

Investing involves risk, including the possible loss of principal. ProShares are generally non-diversified and entail certain risks, including risk associated with the use of derivatives (swap agreements, futures contracts and similar instruments), imperfect benchmark correlation, leverage and market price variance. These risks may pose risks different from, or greater than, those associated with a direct investment in the securities underlying the funds' benchmarks, can increase volatility, and may dramatically decrease performance. Narrowly focused investments typically exhibit higher volatility. Technology companies may be subject to severe competition and product obsolescence. Please see the summary and full prospectuses for a more complete description of risks. **There is no guarantee any ProShares ETF will achieve its investment objective.**

ProShares may invest in equity securities and/or financial instruments (including derivatives) that, in combination, should have similar daily price return characteristics to the fund's benchmark. Derivative contracts are priced to include the underlying index yield and will not generate dividend income. Because ProShares invest in derivatives and other financial instruments, their dividend distributions may not reflect those of their applicable indexes.

"Nasdaq Biotechnology" is a registered trademark of The Nasdaq OMX Group Inc. ("Nasdaq OMX") and has been licensed for use by ProShares. ProShares have not been passed on by Nasdaq OMX or its subsidiaries or affiliates as to their legality or suitability. ProShares are not sponsored, endorsed, sold, or promoted by Nasdaq OMX or its subsidiaries or affiliates, and they make no representation regarding the advisability of investing in these products. **Nasdaq OMX AND ITS SUBSIDIARIES AND AFFILIATES MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO PROSHARES.** ProShares are distributed by SEI Investments Distribution Co., which is not affiliated with the fund's advisor.

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI Inc. ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies Inc. ("S&P"). Neither MSCI, S&P nor any third party involved in making or compiling GICS or any GICS classifications makes any express or implied warranties or representations with respect thereto (or the results to be obtained by the use thereof).

Shares of any ETF are generally bought and sold at market price (not NAV) and are not individually redeemed from the fund. Brokerage commissions will reduce returns.